The MERIT trial offers three essential evidence-based insights for clinical practice in primary membranous nephropathy management. First, obinutuzumab demonstrates substantially superior remission rates—60% higher than tacrolimus—establishing it as a more effective first-line option for eligible patients.
Second, sustained proteinuria reduction at 24 months indicates long-term durability. This sustained benefit is particularly significant given that proteinuria reduction directly correlates with preservation of renal function and reduced progression to end-stage kidney disease.
Third, comparable safety profiles between treatments mean efficacy gains are not offset by increased adverse events, making obinutuzumab a favorable choice from both efficacy and tolerability standpoints. For the approximately 1-2 per 100,000 adults annually diagnosed with this condition, these findings suggest improved clinical outcomes are now achievable through B-cell targeted immunotherapy.
Read the full article on GMJ Newsroom.
Was this article helpful?
